Taiyen Biotech Co., Ltd. (TPE:1737)
Taiwan
· Delayed Price · Currency is TWD 31.60
+0.20 (0.64%)
Mar 10, 2026, 1:35 PM CST
Taiyen Biotech Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 399.87 | 371.52 | 300.39 | 426.7 | 393.23 | Upgrade
|
| Depreciation & Amortization | 245.92 | 217.88 | 197.29 | 194.18 | 188.81 | Upgrade
|
| Other Amortization | - | 0.72 | 0.77 | 0.77 | 0.85 | Upgrade
|
| Loss (Gain) From Sale of Assets | 2.44 | 1.04 | 1.28 | 1.28 | 1.24 | Upgrade
|
| Loss (Gain) From Sale of Investments | -7.61 | -12.85 | -7.43 | 0.36 | 0.54 | Upgrade
|
| Provision & Write-off of Bad Debts | -9.66 | 84.28 | 73.56 | - | - | Upgrade
|
| Other Operating Activities | -2.16 | -99.33 | -82.47 | -38.21 | 24.4 | Upgrade
|
| Change in Accounts Receivable | -14.97 | 79.84 | -85.84 | 104.75 | -215.15 | Upgrade
|
| Change in Inventory | 8.72 | -80.03 | -2.9 | -25.23 | -97.12 | Upgrade
|
| Change in Accounts Payable | -67.92 | 25.68 | 21.35 | -104.6 | 187.74 | Upgrade
|
| Change in Unearned Revenue | -39.58 | 11.73 | -4.2 | 23.21 | 45.84 | Upgrade
|
| Change in Other Net Operating Assets | -83 | 59.64 | 42.74 | -2.52 | 69.71 | Upgrade
|
| Operating Cash Flow | 432.05 | 660.12 | 454.54 | 580.69 | 600.08 | Upgrade
|
| Operating Cash Flow Growth | -34.55% | 45.23% | -21.72% | -3.23% | 76.83% | Upgrade
|
| Capital Expenditures | -300.16 | -307.61 | -341.65 | -246.11 | -388.79 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.17 | 0.01 | - | 0.14 | 0.27 | Upgrade
|
| Sale (Purchase) of Intangibles | -1.63 | - | -3.48 | -0.49 | -2.02 | Upgrade
|
| Sale (Purchase) of Real Estate | - | - | - | - | -1 | Upgrade
|
| Investment in Securities | -28.01 | 14.07 | -29.29 | 1.27 | 28.79 | Upgrade
|
| Other Investing Activities | 58.2 | 5.77 | 35.12 | 15.56 | 11.37 | Upgrade
|
| Investing Cash Flow | -271.43 | -287.76 | -339.3 | -229.64 | -351.38 | Upgrade
|
| Short-Term Debt Issued | 184 | 350 | 290 | 440 | 615.6 | Upgrade
|
| Long-Term Debt Issued | - | - | 20 | 25.26 | - | Upgrade
|
| Total Debt Issued | 184 | 350 | 310 | 465.26 | 615.6 | Upgrade
|
| Short-Term Debt Repaid | -196 | -352 | -210 | -707.53 | -358.07 | Upgrade
|
| Long-Term Debt Repaid | -76.26 | -25.65 | -19.83 | -15.68 | -19.95 | Upgrade
|
| Total Debt Repaid | -272.26 | -377.65 | -229.83 | -723.21 | -378.02 | Upgrade
|
| Net Debt Issued (Repaid) | -88.26 | -27.65 | 80.17 | -257.95 | 237.58 | Upgrade
|
| Common Dividends Paid | -260 | -240 | -300 | -300 | -270 | Upgrade
|
| Other Financing Activities | -14.53 | 1.12 | 20.61 | 9.97 | 3.98 | Upgrade
|
| Financing Cash Flow | -362.8 | -266.53 | -199.22 | -547.98 | -28.44 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.24 | 0.75 | -0.39 | 0.24 | -0.12 | Upgrade
|
| Net Cash Flow | -201.94 | 106.58 | -84.36 | -196.68 | 220.14 | Upgrade
|
| Free Cash Flow | 131.89 | 352.51 | 112.89 | 334.58 | 211.29 | Upgrade
|
| Free Cash Flow Growth | -62.59% | 212.26% | -66.26% | 58.35% | 183.28% | Upgrade
|
| Free Cash Flow Margin | 3.99% | 10.89% | 3.31% | 9.26% | 5.16% | Upgrade
|
| Free Cash Flow Per Share | 0.66 | 1.76 | 0.56 | 1.67 | 1.05 | Upgrade
|
| Cash Interest Paid | - | 6.3 | 3.3 | 4.68 | 5.73 | Upgrade
|
| Cash Income Tax Paid | - | 125.37 | 89.85 | 133.44 | 89.14 | Upgrade
|
| Levered Free Cash Flow | 133.99 | 293.46 | 167.07 | 211.65 | 180.73 | Upgrade
|
| Unlevered Free Cash Flow | 136.1 | 297.42 | 169.16 | 214.48 | 184.44 | Upgrade
|
| Change in Working Capital | -196.75 | 96.86 | -28.84 | -4.39 | -8.98 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.